Buckingham Strategic Partners Alnylam Pharmaceuticals, Inc. Transaction History
Buckingham Strategic Partners
- $5.48 Billion
- Q4 2024
A detailed history of Buckingham Strategic Partners transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Buckingham Strategic Partners holds 862 shares of ALNY stock, worth $216,008. This represents 0.0% of its overall portfolio holdings.
Number of Shares
862Holding current value
$216,008% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ALNY
# of Institutions
667Shares Held
112MCall Options Held
839KPut Options Held
771K-
Capital World Investors Los Angeles, CA16.6MShares$4.16 Billion0.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$3.19 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.39 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.97MShares$1.75 Billion0.35% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.38MShares$1.1 Billion0.64% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $30.8B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...